登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>IL-2 >IL2-H5269

Human IL-2 Protein, Fc Tag (MALS verified)

分子别名(Synonym)

IL2,TCGF,lymphokine,Interleukin 2

表达区间及表达系统(Source)

Human IL-2 Protein, Fc Tag (IL2-H5269) is expressed from human 293 cells (HEK293). It contains AA Ala 21 - Thr 153 (Accession # P60568-1).

Predicted N-terminus: Ala 21

Request for sequence

蛋白结构(Molecular Characterization)

IL-2 Structure

This protein carries a human IgG1 Fc tag at the N-terminus.

The protein has a calculated MW of 41.9 kDa. The protein migrates as 45-50 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

IL-2 SDS-PAGE

Human IL-2 Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

IL-2 SEC-MALS

The purity of Human IL-2 Protein, Fc Tag (Cat. No. IL2-H5269) is more than 90% and the molecular weight of this protein is around 80-98 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

IL-2 ELISA

Immobilized Human IL-2 R alpha, His Tag (Cat. No. ILA-H52H9) at 5 μg/mL (100 μL/well) can bind Human IL-2 Protein, Fc Tag (Cat. No. IL2-H5269) with a linear range of 0.1-2 ng/mL (QC tested).

Protocol

IL-2 ELISA

Immobilized Human IL-2 Protein, Fc Tag (Cat. No. IL2-H5269) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-2 R alpha, His,Avitag (Cat. No. ILA-H82E6) with a linear range of 0.3-20 ng/mL (Routinely tested).

Protocol

IL-2 ELISA

Immobilized Human IL-2 Protein, Fc Tag (Cat. No. IL2-H5269) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-2 R beta, His,Avitag (Cat. No. ILB-H82E3) with a linear range of 0.005-1.25 μg/mL (Routinely tested).

Protocol

 

背景(Background)

Interleukin-2 (IL-2) is an interleukin, a type of cytokine immune system signaling molecule, which is a leukocytotrophic hormone that is instrumental in the body's natural response to microbial infection and in discriminating between foreign (non-self) and self. IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes, the cells that are responsible for immunity. Mature human IL-2 shares 56% and 66% aa sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit crossspecies activity. The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes. IL-2 is also necessary during T cell development in the thymus for the maturation of a unique subset of T cells that are termed regulatory T cells (T-regs). After exiting from the thymus, T-Regs function to prevent other T cells from recognizing and reacting against "self antigens", which could result in "autoimmunity". T-Regs do so by preventing the responding cells from producing IL-2. Thus, IL-2 is required to discriminate between self and non-self, another one of the unique characteristics of the immune system.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
IL-2靶点信息
英文全称:Interleukin-2
中文全称:白细胞介素-2
种类:Homo sapiens
上市药物数量:1详情
临床药物数量:35详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定